Opko Health to Buy Bio-Reference Labs for $1.47B | GenomeWeb

NEW YORK (GenomeWeb) – Opko Health and Bio-Reference Laboratories today announced a definitive merger agreement valued at about $1.47 billion. 

Under the terms of the deal, each Bio-Reference shareholder will receive 2.75 shares of Opko's common stock for each share of Bio-Reference stock. Based on Opko's closing price of $19.12 per share on June 3, the transaction is estimated to be worth $52.58 per share of Bio-Reference's common stock, the firms said. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.